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Rhabdomyosarcoma (RMS), a solid tumour of skeletal muscle
origin, is the most common soft tissue tumour in children,
accounting for approximately 5–8% of all paediatric neoplasias
(Pappo, 1995). Histologically, it can be divided into four cate-
gories: embryonal, botryoid, alveolar, or pleomorphic rhabdo-
myosarcoma (Newton et al, 1995). The embryonal type (eRMS) is
more prevalent and accounts for 50–60% of all cases. It has a more
favourable prognosis affecting predominantly children under 15
years of age in the head-and-neck region. It is characterized by
frequent loss of heterozygosity on chromosome 11p15.5 (Scrable
et al, 1987), expression of myogenic regulatory factors (Tonin
et al, 1991) and deregulated expression of PAX3 and/or PAX7
(Schäfer et al, 1994). Botryoid RMS, a subgroup of the embryonal
type with usually the best prognosis, is almost exclusively found in
young children. Its frequency is about 4–8% of all RMS. The
majority of this RMS type is found in mucosa-lined hollow organs,
such as the nasal cavity, nasopharynx, bile duct, urinary bladder
and vagina. Alveolar RMS (aRMS), an aggressive tumour occur-
ring in children and young adults, is the second most common type
of RMS (18–20%) and is characterized by one of the follow-
ing specific translocations: t(1;13)(p36;q14) PAX7/FKHR or
t(2;13)(q35;q14) PAX3/FKHR (Barr et al, 1993, 1998; Galili et al,
1993; Shapiro et al, 1993; Davis et al, 1994).
Unlike other tissue types, muscle development can serve as
paradigm for understanding the molecular basis of cell lineage
establishment and differentiation. The current picture of myo-
genesis is based on the isolation and characterization of mainly
two families of transcriptional regulators, the muscle regulatory
factors (MRF, including Myf3 (MyoD), Myf4 (myogenin), Myf5
and Myf6 (MRF4)) and the myocyte enhancer factor 2 (MEF2)
family (Ludolph and Konieczny, 1995). Since differentiation and
proliferation are mutually exclusive events, muscle cells can also
serve as a model to investigate cell cycle control. In contrast to
normal myoblasts, RMS cells are blocked in the differentiation
process and have lost growth control.
To facilitate the study of multistage carcinogenesis it is neces-
sary to establish cell cultures that can be used as tumour models in
vitro. Although few RMS cell lines are available, each line has its
specific advantages and disadvantages. The most common used
culture model is the RD cell line that dates from 1969. Like this
cell line, many of the RMS cell lines were derived from relapse
tumours or metastasis, which might not fully reflect the properties
of the original RMS tumour and does not allow to study tumour
progression in vitro. One additional problem is an uncertainty
regarding the origin of some of the lines available. This is espe-
cially true when cells were established from eRMS, have no
specific translocations, and lost in some cases expression of the
characteristic myogenic regulators like Myf3 (MyoD). Then the
generally accepted interpretation would suggest that the original
tumour was misdiagnosed and the cells represent a different
tumour, e.g. Ewing’s sarcoma or primitive neuroectodermal
tumour (PNET).
To obtain additional insight into RMS tumour development, we
started an initiative to isolate and establish additional well charac-
terized cell lines of RMS origin. Our interest is to find and investi-
gate additional factors which might influence the balance between
growth and differentiation in RMS cells, allowing the molecular
characterization of the mechanisms implicated in multistage
development of this neoplasm. In this work, we describe the isola-
tion of a new human cell line derived from a primary botryoid
RMS, and its evolution during time in culture.
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Clinical history
The patient was a 15.5-month old white girl. The tumour was
diagnosed unequivocally as a botryoid rhabdomyosarcoma in the
vagina, belonging to group III of the Intergroup RMS Study
Surgical-Pathological Grouping Classification. The immuno-
histochemistry showed strong staining with antibodies against
vimentin, desmin, a-muscle actin and some weak myoglobin. A
tumour biopsy was taken before any treatment and used to estab-
lish the RUCH-2 cell line. The patient was subsequently treated
with standard chemotherapy and is still in remission.
Mice
Nude mice were maintained under spf (specific pathogens-free)
conditions in the animal facility of the University of Zurich
(Central Biological Laboratory). Experiments were conducted
according to the Swiss ordinance for animal experiments.
Establishment of the RUCH-2 cell line
Primary tumour fragments from the biopsy were injected subcuta-
neously (s.c.) into 4- to 6-weeks old female ICR nu/nu mice. The
xenograft was removed after two passages and minced under
aseptic conditions. The tissue pieces were seeded into a 100-mm
culture dish containing Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
100 units ml–1 penicillin 100 mg ml–1 streptomycin, and maintained
in an incubator at 37°C and 10% carbon dioxide (CO2). The
culture medium was changed three times a week. After reaching
confluence, tumour cells were passaged 1–3 times a week using
trypsin solution. RUCH-2 cells were routinely monitored for
mycoplasma and murine cell contamination by fluorescent
staining with Hoechst 33258, and found to be free of both.
Cell lines
Human cell lines were cultured in DMEM supplemented with 10%
FBS and 100 U ml–1 penicillin and 100 mg ml–1 streptomycin in
10% CO2 and 37°C. The embryonal RMS cell line RD was
obtained from ATCC (Rockville, MD, USA) (McAllister et al,
1969). The embryonal RMS Rh1 and the alveolar RMS Rh30
cell lines were a generous gift from Dr PJ Houghton (St Jude
Children’s Research Hospital, Memphis, TN, USA). The alveolar
RMS cell line RC2 was kindly provided by Dr C De Giovanni
(Istituto di Cancerologia, Bologna, Italy) (Nanni et al, 1986).
Chromosomal studies
Metaphase preparations were obtained according to standard cyto-
genetic methods or for the tumour biopsy as previously described
(Betts et al, 1997). Along with the original tumour, the RUCH-2
cell line was karyotyped at passages 3, 20, 32, 46, 62, 84 and 104.
Cytogenetic analysis and interpretation were made according to
ISCN (1995).
Tumorigenicity of cell lines in vivo
To evaluate the tumorigenic capacity of the RUCH-2 cell line,
cells at passage 30 were injected s.c. into the dorsal region of three
females C57B1/6 nu/nu mice (5–7 weeks old). Each mouse
received 100-ml cell suspension containing 5 ´ 106 viable cells as
determined by trypan blue exclusion. As control an additional
mouse was injected with the same amount of FUCH-1 cells
(normal human fibroblast cell line of the same patient at passage
6) and two further mice were injected with the same amount of RD
cells. The experiment was repeated at passage 67 of the RUCH-2
cell line, whereby ICR nu/nu mice (6–8 weeks old) were used.
Control FUCH-1 and RD cells grew similarly in both mouse
strains.
Invasion assay
The Biocoat® Matrigel® Invasion Chamber was used to perform
invasion assays (Becton Dickinson Labware, Lot 906658). The
chambers, placed in a 24-well plate, were rehydrated with 250 ml
DMEM for 2 h at room temperature. Single-cell suspensions of
different passages of the RUCH-2 cell line were obtained with
5m M EDTA/PBS (phosphate-buffered saline). The cells were
resuspended in 0.1% bovine serum albumin (BSA)/DMEM to a
final volume of 1 ´ 105 cells ml–1. Then, 750 ml 5% fetal bovine
serum (FBS)/DMEM (antibiotica-free) was added to the wells as a
chemoattractant and 500 ml of cell suspension was added to each
chamber. After 22 h non-invasive cells were removed from the
upper surface of the membrane with a cotton swab. The chambers
were then fixed with ice-cold methanol for 10 min and stained
with crystal violet. The membranes were removed, placed on
coverslips and invasive cells were counted under the microscope.
RT-PCR analyses
Reverse transcription polymerase chain reaction (RT-PCR) was
performed using the Access RT-PCR System Kit (Promega) in a
25 ml reaction volume with 100 ng total RNA. As positive and
negative controls, RNA from the established rhabdomyosarcoma
cell lines RD, Rh1, Rh30, or RC2 were used. Total RNA was
extracted using guanidinium-isothiocyanate lysis followed by
centrifugation through a 5.7 M caesium chloride (CsCl) cushion.
All reactions started with reverse transcription at 48°C for 45 min,
followed by a 2-min initial denaturation step at 94°C, and 40
cycles at 94°C for 30 s, 60 or 68°C for 1 min, 68°C for 1 min, with
a final extension at 68°C for 7 min on a PCR system (Perkin-
Elmer Cetus). The 68°C annealing temperature was used only for
the Myf-3 amplification. The FKHR, PAX3 and PAX7 products
were generated in 0.5 mM magnesium sulphate (MgSO4); the
PAX3PAX7/FKHR, Myf-3, and Myf-5 in 1.0 mM MgSO4. The
following primers were used to amplify a 324-bp long fragment of
FKHR [FKHR-F5 5¢-GCAGATCTACGAGTGGATGG-3¢ and
FKHR-F3 5¢-AACTGTGATCCAGGGCTGTC-3¢] (Galili et al,
1993), a 349-bp fragment of PAX3 [PAX3-5¢ 5¢-GCACTGTA-
CACCAAAGCACG-3¢ and  PAX3-REV 5¢-TAGGTGGGTG-
GACAGTAGGA-3¢], a 414-bp fragment of PAX7 [PAX7-3
5¢-GGCGTAAGCAGGCAGGAG-3¢ and PAX7-4 5¢-GCAGCGG-
GGAGATGGAGA-3¢], a 868-bp resp. 862-bp fragment for the
translocations PAX3/FKHR resp. PAX7/FKHR [PAX3PAX7 5¢-
CCAAACACAGCATCGACG-3¢ (this primer anneals to both
PAX3 and PAX7) (Davis et al, 1994) and FKHR-F3], a 159-bp
fragment of Myf-3 [MYF3-FOR 5¢-CTGTGGGCCTGCAAG-
GCGTGCAAG-3¢ and MYF3-REV 5¢-CACCTTGGGCAACCGC-
TGGTTTGG-3¢] (Anand et al, 1994), and finally a 612-bp fragment
of Myf-5 [MYF5-FOR1 5¢-AGCCTGCAAGAGGAAGTCC-3¢ and
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the RT-PCR products were separated by agarose gel elec-
trophoresis.
Hybridization of arrays
Atlas™ Human Cancer cDNA Expression Arrays were purchased
from Clontech (Lot 8090622). mRNAs (RUCH-2 at passage 11
and passage 63) were obtained by isolation of total RNA (CsCl-
centrifugation), followed by treatment with RQ1 RNAase-free
DNase I (Promega). Thereafter poly-A+ RNA was isolated with
a mRNA isolation kit (Boehringer Mannheim), finishing with
a phenol:chloroform:isoamylalcohol (25:24:1) extraction and
ethanol precipitation. 32P-labelled cDNA probes were prepared
from 1 mg of mRNA. Both probes, with a final concentration of
2 ´ 106 cpm ml–1, were hybridized to separate arrays according to
the user manual. The membranes were exposed to Kodak X-ray
films with intensifying screens at – 70°C for different time points.
After hybridization, the results were analysed by autoradiography,
normalizing the blots according to the transcriptional abundance of
the housekeeping genes included on the array (ubiquitin, GAPDH,
a-tubulin, b-actin, 23-kDa highly basic protein, ribosomal protein
S9). As criteria for changes in gene expression, the intensity differ-
ence had to be at least twofold, whereas a more than fourfold
difference was designated as strong alteration.
Northern blot analyses
Total RNA from different passages of RUCH-2 cells was obtained
as previously described under RT-PCR analyses. Five micrograms
of total RNA were used per lane. The probes (inserts coding for
cyclin A (EST clone 2394165), p21 (EST clone 470149), MMP-3
(EST clone 2113735) and the human TIMP-3, Myf3 and Myf5)
were generated by random priming (Prime-a-gene, Promega) with
a32P-dATP and used for hybridization at 68°C with QuickHyb
Hybridization Solution (Stratagene) according to the manufac-
turer’s instructions. The membrane was exposed to Kodak X-ray
films and was reprobed thereafter.
RESULTS
Isolation of the cell line
To establish a cell line from the tumour specimen, mice were
subcutaneously (s.c.) injected with minced tumour pieces. After 5
weeks, the tumour was resected and placed in culture. In parallel,
some tumour material was injected again into a nude mouse. In
culture, morphologically distinct cells grew rapidly out of the
tumour pieces; however, the homogenous cell population finally
resulting after several passages was identified as human fibroblasts
by morphology, karyotype analysis, as well as RT-PCR experi-
ments for myogenic markers (see below). Therefore this cell line
was called FUCH-1 (for Fibroblast of University  Children’s
Hospital).
After the second xenograft reached 5 mm in diameter (3 months
in total), it was minced and placed in culture. This time no human
fibroblasts could be detected by microscopic examination. The
cells appeared mostly elongated and spindle-shaped with a few
multinucleated cells detectable. Molecular characterization clearly
established that these cells are derived from the original tumour
(see below). Compared to other RMS cell lines these cells are
rather large. The resulting cell line was called RUCH-2
(Rhabdomyosarcoma of University Children’s Hospital) and is in
continuous culture since 16 July 1997. As expected, the cells
underwent a crisis in culture around passage 32–38 (~ 3.5 months
in culture). They became extremely flat and almost stopped
dividing. Then, they started to proliferate again which was accom-
panied by phenotypic changes to polygonal homogenous cells,
resembling myogenic precursor cells (Figure 1). These morpho-
logical observations were later confirmed on the molecular level
(see below).
The RUCH-2 cells were split 1:2 every 65–72 h until passage 30
(P30), and every 48 h after P47. Interestingly, cells below P30
synthesized extensive extracellular matrix as evidenced by a
gelatinous appearance of the culture supernatant, which disap-
peared after P38. These results demonstrate that we could
successfully establish a new cell line derived from a botryoid
rhabdomyosarcoma.
Karyotype analyses of RUCH-2 cells
To better characterize and monitor possible changes in the RUCH-
2 karyotype, cells were analysed at passage 3, 20, 32, 46, 62, 84
and 104 and compared with the original tumour. Cytogenetic
investigation of the original tumour revealed a karyotype of:
54~57,X,–X,+7,+inv(7)(q11q32),+8,+8,+12,+13,+13,+19,+20,
+21,+r,+0~2mar[cp6].
In comparison, initial analysis of the cell line (at P3) demon-
strated a karyotype of:
55,X,–X,+7,+inv(7)(q11q32),+8,+8,+12,+13,+13,+19,+20,+21
/55,idem,del(20)(q13)[cp40].
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Figure 1 Morphology of RUCH-2 cells. (A) Phase contrast picture of low
passage (P22) and (B) high passage (P63) RUCH-2 cells (100 ´
magnification)Hence, this karyotype was essentially identical to the one of the
original tumour. Further analysis at passages 20 and 32 displayed a
similar karyotype without any major changes. Hyperdiploidy, as
seen here, with few structural aberrations appears to constitute a
distinct karyotype subgroup in RMS (Wang-Wuu et al, 1988). A
different, earlier, study of ten eRMS tumour samples showed
gain of the whole or a large part of various chromosomes, notably
chromosomes 2 (60% of cases), 7 (50%), 8 (60%), 12 (60%), 13
(60%), 17 (40%), 18 (40%) and 19 (40%) (Weber-Hall et al,
1996). Hence, the original tumour and the cells up to P32 reflect
many of these described alterations by displaying a gain of chro-
mosomes 7, 8, 12, 13 and 19.
Interestingly, marked changes in the karyotype were observed
starting from P46. Initially, we detected large cell to cell variation
with the simplest clone being near triploid and containing multiple
additional rearrangements. Also present was a distinct polyploid
population and some metaphases with double minutes (dmin).
Cells with dmin continued to be present at P62, but were no longer
detected at P84. The final analysis at P104 showed a karyotype of:
67,X,add(X)(p11),–X,add(1)(q12)x2,del(1)(p34),+del(1)(p21),
–2,t(3;12)(q21;p13),–6,–9,–9,add(9)(p12),–10,der(11)t(1;11)
(p22;q22),add(12)(q13),der(12)t(3;12)(q21;p13),–13,–14,add
(16)(q12),–17,add(18)(q23),der(18)t(?17;18)(q21;q23),+20,
+20,–21,–22,– 22,+4~5mar[cp50].
The above karyotype showed at this point only limited cell to
cell variation anymore. However, with the exception of the
add(X)(p11) and the del(1)(q12), all major structural rearrange-
ments were already present at P46. In contrast certain rearrange-
ments identified at P46 were lost thereafter, such as a del(2)(p22),
add(9)(q34) and add(17)(p11). These might have been apparent
precursors for the subsequent loss of the entire chromosomes.
Among the abnormalities acquired between P32 and P46 those of
del(1p), t(3q), –9, add(9p) and add(18q23) have been previously
reported and/or observed in primary RMS samples karyotyped at
our hospital (data not shown). Hence, the RUCH-2 karyotype at
late passage (P104) had karyotypic similarities to primary metas-
tasis or relapse RMS tumours. Based on these results the changes
of RUCH-2 cells observed during evolution in culture show some
interesting parallels to normal RMS tumour progression.
Induction of metastasis in late passage RUCH-2 cells
To examine their tumorigenic potential, 5 ´ 106 RUCH-2 cells at
early and late passages were injected s.c. into nude mice. The
control cell line FUCH-1, normal human fibroblasts (judged by
karyotyping) of the same patient, did not lead to tumour growth
even after 3.5 months of observation. In contrast RUCH-2 cells at
P30 induced, in two out of three mice, tumours of 4–6 mm in
diameter after 3.5 months, which is about a quarter of the size of
tumours induced by the established RMS cell line RD. In none of
the animals obvious metastases were observed.
Next, we used RUCH-2 cells at P67. Whereas tumours grew to
the same size as cells at P30 in all three mice, one animal had to be
sacrificed after ~2.5 months because of metastasis. After dissec-
tion numerous huge metastases were observed in the liver and the
spine. Both, the xenographed tumours and the liver metastases
were confirmed to be of RMS origin by immunohistochemical
investigations demonstrating desmin, myoglobin and a-skeletal
actin staining (data not shown), whereby the metastasis showed
more intense staining. A similar result was obtained with a second
animal, whereas only a small tumour grew in a third animal. In
contrast, no metastases were detected in mice injected with RD
cells. These results suggest that RUCH-2 cells progressed in
culture to acquire a metastatic phenotype.
In vitro invasivity of the RUCH-2 cell line
The notion that metastases were observed in two out of three mice
injected with late passage RUCH-2 cells suggested that the cells
gained metastatic properties including the ability to invade extra-
cellular matrix. To confirm this suggestion in vitro, modified
Boyden chambers were used to measure the ability of the cells to
invade extracellular matrix. At P21–31, 8.7 to 11.5 cells invaded
the matrigel, in contrast to P66–141 where 65.5 to 67.7 cells were
counted (see Materials and Methods) (Figure 2). Hence, late
passage cells were significantly (eightfold) more invasive than
cells at early passages supporting the observation that they
acquired a more invasive and metastatic phenotype.
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Figure 2 In vitro invasiveness of RUCH-2 cells. Cells at different passages
were analysed for their invasive behaviour. Low passage cells, P21–22 and
P29–31 (striped bars), were compared with higher passages, P66–68 and
P140–141 (black bars). The number of cells which invaded the matrigel was
determined after staining with crystal violet and counting under the
microscope. Data represent mean values ± s.e.m of three independent
experiments
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Figure 3 Expression of Pax genes and members of the Myf gene family in
human cell lines. One hundred nanograms of total RNA per RT-PCR reaction
were used. All cell lines (RUCH-2, RD, Rh1, Rh30, and RC2) are RMS,
except FUCH-1, which is a fibroblast line. FKHR was amplified as an internal
control for RNA quality. RT-PCR products were electrophoresed in 1–2.5%
agarose gels, stained with ethidium bromide. A 100-bp ladder was used as
marker (strong band = 600 bp). The expected length of the PCR products
are indicated at the leftMolecular characterization of RUCH-2
To get insight into possible molecular changes accompanying the
observed biological behaviour of RUCH-2 cells, we first analysed
the expression pattern of regulatory proteins known to be involved
in muscle differentiation. RT-PCR analyses were performed to
characterize possible changes in the expression of PAX transcrip-
tional regulators and myogenic determination factors (Myf). As
controls, cell lines were used which provide either positive or
negative controls for every RT-PCR reaction. FKHR was ampli-
fied as a control for RNA quality. As shown in Figure 3, similar
FKHR levels could be detected in all samples, indicating integrity
of the RNAs. RT-PCR results further showed that RUCH-2 cells
express PAX3, similar to other RMS cell lines (RD, Rh1, Rh30
and RC2). Only the corresponding fibroblast cell line did not
express PAX3 confirming the aberrant expression of PAX3 in
RMS. Neither translocation products (PAX3/FKHR, PAX7/
FKHR) nor PAX7 expression could be detected in RUCH-2 cells.
Myf3 expression is assumed to be characteristic for RMS tumours
and cell lines (Clark et al, 1991) and was also detected in RUCH-2
(Figure 3, lane 2). In addition, Myf5 is expressed in RD and
RUCH-2 cells, whereas Myf4 was detected in RD, RC2, and very
weakly in Rh30 but not in RUCH-2 and Rh1 cells (data not
shown). Since both myogenic markers Myf3 and Myf5 were
expressed in RUCH-2 cells at P3, the myogenic origin of the
RUCH-2 cell line could be confirmed on the molecular level.
To monitor possible progression in culture, RT-PCR investiga-
tions were repeated at passage 6, 31, 47, and 64 (Figure 4).
Interestingly, Myf3 and Myf5 transcripts were no longer detected
after P31 (results confirmed by Northern blot analyses, see Figure
5), whereas FKHR and PAX3 expression remained constant.
Hence, the appearance of a metastatic population was associated
with changes in the karyotype as well as alterations in the expres-
sion levels of myogenic regulatory factors, Myf3 and Myf5, whose
expression was down-regulated in late passage RUCH-2 cells.
Differential gene expression in early and late passage
RUCH-2 cells
To monitor global changes in expression pattern of genes likely to
be involved in tumour progression, expression of 588 cancer and
metastasis-related genes were simultaneously examined using
cDNA microarray hybridization. Gene expression was monitored
using 32P-labelled cDNA generated from RNA isolated from cells
at P11 and P63. Ninety-two genes displayed altered expression
levels between non-metastatic and metastatic cells, representing
almost every sixth gene investigated. Of these 92 genes, 64 were
down-regulated in high passage RUCH-2 cells, 17 of them
strongly. In contrast, 28 investigated cDNAs were up-regulated
including five strong ones. To facilitate the identification of
potentially important genes and because of the large number of
alterations observed, three functional categories were selected and
examined in more detail, namely apoptosis-related genes, proteases
and protease inhibitors, and cell cycle regulators. Genes from these
categories showing altered expression are listed in Table 1. The
complete list of the 92 differentially expressed genes in all categories
can be viewed at our homepage: http://www.unizh.ch/kispi/
clinchem_html/schafer.html. To independently confirm the alter-
ations observed in the microarray, additional Northern blot analyses
were performed using several different passages of RUCH-2 RNA
(Figure 5). These experiments revealed that the expression of genes
analysed from different functional groups strictly correlated with
expression data from the microarray study: up-regulation of MMP-3
and, to a lesser extent, cyclin A, down-regulation of TIMP-3 and
p21. Additionally, loss of expression of myogenic markers, as seen
in RT-PCR experiments (Figure 3), could be confirmed quantita-
tively (Myf3, Myf5).
Looking at the differentially expressed genes in Table 1, exten-
sive changes in the composition of the extracellular matrix were
observed. Furthermore, as could probably be expected, this was
accompanied by down-regulation of tissue inhibitors of metallo-
proteinases (TIMP) and up-regulation of some matrix metallo-
proteinases (MMP). Genes of particular interest might include
MMP-14 and TIMP-2, since coexpression of both genes during
Multistage tumorigenesis in rhabdomyosarcoma 1243
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Figure 5 Northern blot analyses of RUCH-2 cells at different passages.
The indicated genes (MMP-3, TIMP-3, cyclin A, p21, MYF3, MYF5) were
analysed sequentially on the same blot. TIMP-3 showed a downregulation
for all three splice variants. The amount of total RNA was confirmed with a
b-actin probe
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Figure 4 Expression of myogenic regulators at different passages of
RUCH-2 cells. RT-PCR reactions were performed with RNA isolated from
cells at different passages. FKHR was amplified as an internal control for
RNA quality. RT-PCR products were loaded on agarose gels and stained
with ethidium bromide. As marker a 100-bp ladder was used (strong band =
600 bp). The expected length of the PCR products are indicated at the left
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b-actinmuscle development has been reported (Apte et al, 1997). In
addition, the extracellular matrix metalloproteinase inducer
(EMMPRIN), expressed on the cell surface, was down-regulated.
Its absence in the vertical growth phase and in metastatic lesions
of melanomas suggests that other factors are involved in tissue
degradation during later stages of tumour progression in malignant
melanoma (van den Oord et al, 1997). Furthermore, strong up-
regulation of plasminogen activator inhibitor 2 (PAI-2) was coor-
dinated with a decreased expression of tissue-type plasminogen
activator (t-PA). Indeed low t-PA and high PAI-2 levels have been
correlated with poor overall survival in a number of primary
tumours of different origin (Andreasen et al, 1997).
Interestingly, we also observed strong down-regulation of death
receptors belonging to the tumour necrosis factor and nerve
growth factor superfamily, namely DR3, CD27 and TNFR1. This
suggests a possible hampered response of high passage RUCH-2
cells to appropriate apoptotic stimuli. In support of this, the
signalling kinase Akt-1, a strong mediator of cell survival, is
overexpressed as well in late stage RUCH-2 cells. However,
contrasting this potential progression towards apoptosis resistance,
two anti-apoptotic molecules, bag-1 and A1 (bfl-1) were also
down-regulated. Hence, not single alterations but a complex coor-
dinated up- and down-regulation of molecules involved in regula-
tion of apoptosis was observed, which might shift the balance of
the cellular response into one particular direction. This can also be
seen when analysing genes involved in cell cycle regulation. Most
prominently, cyclin A and cyclin B1 were up-regulated (stimu-
lating progression through the cell cycle), whereas cyclin D1 as
well as cyclin G1 were down-regulated (slowing progression).
Furthermore, a striking down-regulation is seen for the cell cycle
inhibitor p21 (again stimulating progression). Here, as a net result
from these complex alterations, the proliferation rate of the cell
population increases.
In summary, we identified a large number of genes whose
expression is altered during RUCH-2 progression. Some of these
might play a predominant role in tumour progression towards
the metastatic phenotype that can now be further evaluated in
additional investigations, involving primary tumour samples.
DISCUSSION
In this work we describe the isolation and molecular characteriza-
tion of a new human cell line derived from a botryoid RMS. The
key feature of this new cell line is its availability at low, non-
metastatic and high, metastatic, passages following a spontaneous
progression in vitro. This provides an interesting cellular model,
since cells could initially be established from the original tumour
not under treatment at time of biopsy.
Unlike other cell culture models of metastasis which are mostly
based on single clone selection, progression observed in the
RUCH-2 cell line occurred spontaneously in the population. We
provide here three different experimental criteria demonstrating
this evolution: changes in morphology and enhanced growth rate,
gain of invasiveness through matrigel in vitro and, finally, de novo
appearance of metastases in a nude mouse model in vivo.
How does tumour progression in culture relate to in vivo
progression? Genome instability and resulting selection of
subpopulation underlie progression in vitro as well as in vivo.
However, because of culture conditions, different subpopulations
might be selected. To assess this notion frequent examinations of
the tumour cell karyotype were carried out. These cytogenetic
investigations revealed that the karyotype in early passages was
very similar to the original tumour. However, in later passages, a
number of chromosomal gains and rearrangements were observed.
Strikingly, several of the breakpoints which were newly observed,
namely 1p21, 3q21, 12p13, 12q13 and 17q21 seem to be non-
random, since they were also reported in primary RMS tumour
samples (Whang-Peng et al, 1992; Kullendorff et al, 1998). This
also includes a rather rare breakpoint at 18q23. Although compar-
ison between in vitro and in vivo progression is clearly very
limited, RUCH-2 cells represent, to our knowledge, the only
progression model for human RMS available and hence provide a
starting point for the identification of novel genes involved in
rhabdomyosarcoma progression.
To begin to investigate possible molecular alterations in
progression, we first performed RT-PCR experiments to study the
expression levels of selected known regulatory molecules. While
RUCH-2 cells at all passages expressed PAX3, the expression of
the myogenic regulators Myf3 and Myf5 was restricted to early
passages and completely disappeared later on as demonstrated by
RT-PCR and quantitative Northern blot analysis. These results
have implications for other tumour cell lines which are thought to
be of RMS origin, since doubts have been expressed over their
origin based on the missing expression of the myogenic regulatory
proteins. Examples of such publicly available cell lines are A204
and Hs729. Our results suggest that they should not be excluded as
having RMS origin, especially when they have been cultivated for
an extensive period. On the other hand, analysis of Myf genes in
primary RMS tumours revealed that only 18 out of 20 samples
displayed Myf gene expression (Clark et al, 1991). Interestingly, a
second RMS cell line established in our group, RUCH-3, which
was derived from a relapse embryonal RMS, did never express
Myf3 and Myf5, but PAX3 (the patient died a short time after exci-
sion). Hence, lack of Myf3 might be confined to more advanced
tumour stages.
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Table 1 Differential gene expression 
(RUCH-2 P63 compared to RUCH-2 P11)
Gene
Functional categorya Down-regulated Up-regulated
Apoptosis-related Caspase-2 Caspase-4 + caspase-5
TNFR1 Akt-1
A1c
Bag-1c
DR3c
CD27c
Proteases and inhibitors MMP-14 MMP-3c
TIMP-1 MMP-8c
TIMP-2 PAI-2c
TIMP-3
EMMPRIN
t-PA
LRP
Cell cycle regulatorsb cyclin D1 Cyclin A
cyclin G1 Cyclin B1
p21c
aOnly selected categories and bgenes, entire list presented on our
homepage:http://www.unizh.ch/kispi/clinchem_html/schafer.html; cstrong
alterations.To provide a more comprehensive analysis of the molecular
changes involved in metastatic progression, we then applied the
cDNA microarray technique to compare expression of 588 known
tumour-associated genes from late with early passage cells. The
microarray hybridization most likely reflects true changes in
expression level, because the alteration of selected genes like
TIMP-3, MMP-3, cyclin A and p21WAF1 could be confirmed with
quantitative Northern blot analyses of RUCH-2 cells at various
passages (Figure 5). As expected, a number of alterations (either
up- or down-regulation) were observed in the composition of the
extracellular matrix, including enhanced expression of
proteinases. However, other alterations might provide novel
insight into RMS development. Some of the most striking changes
were observed in the category of apoptosis-related genes, where
the down-regulation of three receptors of the TNF receptor family,
namely TNFR1, DR3 and CD27, was very prominent. So far,
neither the expression nor the role of these death receptors has
been investigated in skeletal muscle cells. Down-regulation of
death receptors has, however, been correlated with the develop-
ment of other cancers, e.g. TNFR1 in non-small-cell lung cancer
(Wyllie, 1997; Tran et al, 1998). Furthermore, an enhanced resis-
tance of metastatic cancer cells to programmed cell death has been
described for several neoplasms (Glinsky et al, 1997; Takaoka et
al, 1997). Hence, these receptors could play an important role in
RMS development as well. Interestingly, TNFR1 and CD27 are
both located at 12p13, a locus where rearrangements have been
observed in high passage RUCH-2 cells, raising the possibility that
their expression might be influenced by the translocation event.
A more extensive use of DNA microarray technology should
undoubtedly allow the identification of additional changes impor-
tant for RMS progression in the near future. Evidently, all changes
will have to be verified in additional RMS cells and, ideally, biopsy
samples from primary tumours as well as metastases from the same
patient. Nevertheless, the RUCH-2 cell line provides a starting
point for the identification of progression associated genes in RMS,
genes which might be important for other tumours as well.
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